<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321475</url>
  </required_header>
  <id_info>
    <org_study_id>A-38-00240-138</org_study_id>
    <nct_id>NCT02321475</nct_id>
  </id_info>
  <brief_title>EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders</brief_title>
  <acronym>TAYPES</acronym>
  <official_title>Non-interventional Prospective Observational Survey to Describe EGb 761® (Tanakan®) Effectiveness in the Treatment of Patients of Middle Age and Younger With Psycho-emotional Symptoms, Added to Cognitive Disorders.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness of EGb 761® (Tanakan®) in Russian
      patients of middle age and younger, suffering from psycho-emotional symptoms added to
      cognitive disorders based on the improvement of FAM test (feeling-healthy, activity, mood
      test) score.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with increase of total medium FAM test score ≥1 after 3 months treatment</measure>
    <time_frame>3 months</time_frame>
    <description>The FAM test is a questionnaire using three subscales (i.e. General health, Activity, and Mood). Scores for each subscale range from 3 to -3 (where -3 is bad and 3 is good). The total for each subscale and arithmetical mean is calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of total medium FAM test score.</measure>
    <time_frame>3 months</time_frame>
    <description>The FAM test is a questionnaire using three subscales (i.e. General health, Activity, and Mood). Scores for each subscale range from 3 to -3 (where -3 is bad and 3 is good). The total for each subscale and arithmetical mean is calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of short-time verbal memory</measure>
    <time_frame>3 months</time_frame>
    <description>Investigator to assess short-time verbal memory using a set 10-words recall test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of attention</measure>
    <time_frame>3 months</time_frame>
    <description>Attention assessed using a digit-symbol coding test. The digit symbol score is the percentage of correct symbols completed in 90 seconds.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who answered &quot;Completely satisfied&quot;, &quot;Rather satisfied&quot;, &quot;Neither satisfied nor dissatisfied&quot;, &quot;Rather dissatisfied&quot; or &quot;Completely dissatisfied&quot;, when assessing their satisfaction with Tanakan®</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">54</enrollment>
  <condition>Cognitive Disorders</condition>
  <arm_group>
    <arm_group_label>Psycho-emotional symptoms, added to cognitive disorders</arm_group_label>
    <description>Patients of middle age and younger with psycho-emotional symptoms, added to cognitive disorders.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGb761®</intervention_name>
    <arm_group_label>Psycho-emotional symptoms, added to cognitive disorders</arm_group_label>
    <other_name>Tanakan®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Middle-age or younger patients with cognitive disorders and psycho-emotional symptoms
        (principal diagnosis).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who signed the Informed Consent for participation in the observational study
             before collection of any information

          -  Patients who complain of psycho-emotional disturbance (of any intensity)

          -  Men and women aged 18-45 years, who prescribed to receive Tanakan® for cognitive
             disorders

        Exclusion Criteria:

          -  Presence of any contraindications listed in the Tanakan® local SmPC (hypersensitivity
             to any of the components of Tanakan®, pregnancy, lactation, erosive gastritis in acute
             phase, gastric ulcer and duodenum ulcer in acute phase, acute cerebrovascular
             accident, acute myocardial infarction, congenital galactosemia, lactase deficiency,
             glucose-galactose malabsorption, haemolysis)

          -  Presence of dementia (according to Diagnostic and Statistical Manual of Mental
             Disorders [DSM IV])

          -  Disturbance of usual activities of daily living (e.g. self-care)

          -  Patients taking antipsychotic drugs, antidepressants, tranquillisers and nootropic
             agents

          -  Presence of any severe disease or condition which could affect cognitive function
             (e.g. Parkinson disease, epilepsy, brain inflammatory disease, major depression,
             recent post-stroke condition, recent brain-trauma etc.);

          -  Presence of anxiety or depression according to the Hospital Anxiety and Depression
             Scale (11 points and more).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elena Poznyakova, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Russian National Research Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>117152</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Moscow State Medical University</name>
      <address>
        <city>Moscow</city>
        <zip>119435</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <last_update_submitted>June 29, 2015</last_update_submitted>
  <last_update_submitted_qc>June 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psycho-emotional symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Cognition Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

